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Letters to the EditorStarting from January 2001,we have
established a structured program ap-
proved by the research ethics board of
our academic Institution.2 After more
than a decade of experience,3-5 we
believe that a surgeon should awarded
privileges in performing a regular
number of such procedures by the
institution administrators. We suggest
that proficiency in awake thoracic
surgery be certified and listed as
a credential in submitting applications
for surgical positions. Certification in
awake surgery should be also given to
operating room staff, including
dedicated thoracic anesthesiologists,
scrub nurses, and technicians.
Commitment to maintain the same
team for at least 40 procedures a year
should be also provided.
It is nice for us to read favorable
and more frequent studies about this
awake anesthesiology pattern. We
therefore encourage thoracic sur-
geons to perform these procedures
and submit their statistics to an insti-
tutional database, thus providing an
excellent tool for evidence-based sur-
gery. Those educational centers
where this modern program is adop-
ted should establish cooperative net-
works with each other and should
accurately popularize the benefits of
the treatment among physicians and
patients. In addition, such educa-
tional tools as dry and wet labs, oper-
ating room simulations and lecture
series should form an active part of
this program. Finally, to conduct
a successful and safe awake thoracic
operation, the surgeon must be aware
of both short- and long-term out-
comes and must be updated with
the latest advances in this field.
In the end, we are firmly convinced
that this field of surgery is ripe for fur-
ther developments.
Tommaso Claudio Mineo, MD
Vincenzo Ambrogi, MD, PhD
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j.jtcvs.2012.06.061HEMOSTATIC MANAGEMENT
IN COMPLEX AORTIC
SURGERY: A ROLE
FOR MULTIPLE ELECTRODE
AGGREGOMETRYAND
MODIFIED ROTATIONAL
THROMBOELASTOMETRY
To the Editor:
We read with a great interest the
recently published retrospective
propensity-matched analysis by
Goksedef and colleagues,1 who
matched 58 cardiac surgical patients
in a recombinant activated factor VII
(rFVIIa)–treated group (n ¼ 29) and
a control group (n ¼ 29). Patients
were compared with respect to reex-
ploration, mortality, bleeding-related
events, use of blood and blood prod-
ucts, duration of intensive care unit
stay, duration of hospitalization, and
thrombotic complications.1 We agree
with the statement of Goksedef and
colleagues1 that strategies to prevent
coagulopathic bleeding are essential
for the successful management of
patients undergoing complex aortic
operations. We do, however, have
a few comments and suggestions for
hemostatic management in such com-
plex cases.
In our opinion, data regarding pre-
operative antiplatelet therapy
management are lacking. We are in-
terested to know whether matchedCardiovascular Surgery c December 20patients were preoperatively exposed
to antiplatelet therapy (eg, aspirin).
Was the proportion of patients ex-
posed to antiplatelet therapy different
among the matched groups? There is
some evidence that certain patients
have an accentuated response to the
usual doses of preoperative aspirin
that may result in increased perioper-
ative blood loss.2 The use of suitable
point-of-care platelet function ana-
lyzers thus seems to be reasonable
in this field. Such an approach in
the preoperative phase can discrimi-
nate patients with accentuated plate-
let inhibition and allow the
possibility of early discontinuation
of antiplatelet drugs before surgery
for patients with intensive platelet
inhibition.
Furthermore, the results of the
study by Goksedef and colleaguesl1
are not in line with recently published
results by Chapman and coworkers,3
who also compared cardiac surgical
patient outcomes with respect to
rFVIIa administration. In the study
by Chapman and coworkers,3 a group
of patients treated with rFVIIa did
have significantly higher rate of reop-
eration for bleeding, a 2-fold increase
in the use of blood products, and more
frequent pulmonary complications. In
addition to this, Hacquard and associ-
ates4 reported that 20% of patients
who received rFVIIa continued to
bleed severely despite the rFVIIa
therapy.
In our opinion, rFVIIa represents
a valuable therapeutic option in cases
of intractable bleeding; however, it
should be administered after other
useful treatment modalities have
been exhausted. For example, Spiess
and coworkers5 reported that throm-
boelastographically guided hemo-
static management significantly
reduced both overall transfusion and
mediastinal reexploration for
excessive bleeding. In addition, the
preliminary results of our research
project (under clinicaltrials.gov
identifier NCT01281397; data not12
Letters to the Editorpublished, manuscript in preparation)
showedmodified rotational thromboe-
lastometry and multiple electrode ag-
gregometry results as predictors of
excessive bleeding after cardiac surgi-
cal procedures. Preoperative platelet
function assessment and intraopera-
tive hemostatic property optimization
guided by thromboelastometry can
reduce the tendency toward excessive
bleeding, leading to diminished use of
rFVIIa with even better efficiency
after functional hemostatic properties
optimization before rFVIIa adminis-
tration. It is noteworthy that concomi-
tant use of multiple-electrode
aggregometry and modified rotational
thromboelastometry can help to
discriminate excessive bleeding as
a surgical or a coagulopathic bleeding.
Any rFVIIa administration should
follow previously mentioned preoper-
ative and intraoperative hemostatic
optimization measures determined
from suitable bedside hemostatic
monitoring devices with a short time
frame from blood sampling to getting
results. In our experience, such an
algorithm can help in reducing both
chest tube output and blood product
transfusion requirements, with
onlysporadic need for rFVIIa
administration.
We congratulate Goksedef and col-
leagues1 on their elegant and timely
research.
Mate Petricevic, MDa
Bojan Biocina, MD, PhDa
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OF POSTINFARCT SEPTAL
RUPTURE REVISITED
To the Editor:
We readwith great interest and sense
of nostalgia the brief report on the tech-
nique of perventricular device closure
in post–myocardial infarction septal
defect by Love and colleagues1 in
2011. They reported 2 cases of cardio-
genic shock aftermyocardial infarction
with septal defects sized 25 and 28mm.
They used the Amplatzer septal oc-
cluder (St Jude Medical, Inc, St Paul,
Minn) sized 34 mm through a 12F
and13-cmCook (CookGroup Incorpo-
rated, Bloomington, Ind) sheath ad-
vanced over a guide wire. The large
50-mm left disk of the Amplatzer de-
vice was placed flush with the septum
anddelivered in the left ventricular cav-
ity. Then, with traction on the delivery
system and countertraction on the right
ventricular free wall, the proximal disk
was deployed exteriorly on the right
ventricular surface. After detachment
of the device from the delivery system,
they went on to tie the purse-string
suture and sutured a piece of bovine
pericardium between the right ventric-
ular free wall and the device to prevent
device erosion caused by movement.
Both patients had an uneventful recov-
ery despite a small residual ventricular
septal defect, and early discharge
from the hospital compared with con-
ventional open techniques of repairof Thoracic and Cardiovascular Surger(though one of them needed an addi-
tional ventricular septal defect muscu-
lar occluder inserted transfemorally
on the 10thpostoperative day).Of these
2 patients, 1 continued to do well 13
months postoperatively; however, after
3 weeks the other returned in a state of
profound low cardiac output and died
despite a minimal residual ventricular
septal defect, primarily because of
biventricular myocardial failure.
Although Love and colleagues1
noted that they were unaware of any
previous such reports in the indexed
literature,wewould like to take this op-
portunity to bring readers’ attention to
our previous presentation, the world’s
first case report video with this hybrid
technique in 2006.The techniquevideo
with 13-month follow up was pre-
sented in the teaching video sessions
of the 2008 annual conference of the
International Society of Minimally
Invasive Cardiothoracic Surgery meet-
ing in Boston . The abstract was pub-
lished in the Society’s official journal
Innovations.2
This 62-year-old male, hyperten-
sive, nondiabetic patient presented in
cardiogenic shock as a result of infe-
rior wall myocardial infarction, which
also involved the right ventricle, and
anuria. The patient was initially man-
aged with an intra-aortic balloon
pump for 9 days. As urine started
flowing and renal function improved,
coronary arteriography revealed criti-
cal triple vessel disease with a left
ventricular ejection fraction of 30%
and a right ventricular ejection frac-
tion of 25%. The patient had a septal
aneurysm on the right ventricular
side, with multiple sievelike septal ne-
croses (type III dissecting septal rup-
ture) measuring 18 mm. In view of
the prohibitive risk of conventional
open surgery in this situation, we
(like Love and colleagues1) involved
a pediatric cardiologist and decided
to use transesophageal echocardiogra-
phy for hybrid imaging and off-pump
triple bypass. This included a left in-
ternal thoracic artery graft to the left
anterior descending coronary arteryy c Volume 144, Number 6 1535
